A University of Minnesota-led team discovered a highly potent small molecule, MWAC-3634, that blocks Ebola virus entry by stabilizing the virus's entry protein. The compound shows strong protection when given orally in a preclinical model.
Two studies on the 2026 Bundibugyo virus outbreak highlight new approaches to rapid diagnostics and vaccine preparedness. Diagnostic tests can be evaluated rapidly during an outbreak, and the 2026 virus may offer some cross-protection with existing Ebola vaccines.
The Osaka Metropolitan University, K.K. DNAFORM, and INRB have developed a portable rapid diagnostic system for Ebola virus disease caused by Bundibugyo virus. The system utilizes the GenPad POCT platform and can be used near outbreak sites without power infrastructure.
A recent hantavirus outbreak on a nature cruise has sparked concerns about the potential for a global pandemic. Experts warn that Ebola-like viruses pose significant threats to public health.
JMIR Publications invites submissions on the 2026 Ebola disease public health emergency of international concern, focusing on response strategies, risk communication, and surveillance. The World Health Organization has declared a public health emergency due to population mobility and ongoing uncertainty in the Democratic Republic of th...
A growing DRC Ebola outbreak has confirmed transmission in Uganda, and experts estimate a 70% chance of it spreading to South Sudan. The virus is potentially on course to reach South Sudan due to busy border crossings.
Hantavirus and Ebola virus disease are two deadly infectious diseases that require rigorous infection and prevention control (IPAC) practices. Both diseases present with similar early symptoms and can be treated effectively with proper precautions.
A study analyzing all known Ebola disease cases outside Africa since 1976 found a low overall risk of exportation. Local, community-based case management and infection prevention at the outbreak source are considered key strategies to mitigate transmission risk.
Researchers found that Ebola virus can persist in cerebral organoids for up to 120 days, infecting various cell types, including neurons and astrocytes. The virus can trigger local inflammation and lead to disease relapses in survivors, highlighting the need for improved treatments.
Elsevier has launched its Ebola Information Center, providing free access to critical clinical and research information to support the global response to the outbreak. The center combines evidence-based clinical guidance, peer-reviewed research, and AI-assisted tools to aid in rapid evidence discovery and response coordination.
The Global Virus Network will host an international media briefing on the ongoing Ebola outbreak in the Democratic Republic of Congo. Frontline experts from the DRC, WHO, Africa CDC, and leading Ebola researchers will discuss outbreak response, diagnostics, vaccines, and therapeutics.
A new predictive model developed at Washington State University can identify the reservoirs of emerging zoonotic viruses and dangerous pathogens like Ebola. The model uses serological data and seasonal biological patterns to narrow down when viruses are most likely to be found in wildlife.
Researchers at Southwest Research Institute (SwRI) and Texas Biomedical have identified nearly two dozen antiviral compounds that could potentially treat Bundibugyo Ebolavirus. The project utilizes AI and machine learning tools to quickly identify drug candidates, with Texas Biomed set to screen the compounds in the coming weeks.
The Global Virus Network calls for greater financial, logistical and research support for the local response to the Bundibugjo Ebola virus outbreak in Africa. The spread of this virus underscores the global threat posed by viral outbreaks, with no readily available diagnostics or treatments.
Researchers at Wake Forest Institute for Regenerative Medicine have identified a unique gene pattern specific to Ebola, allowing doctors to distinguish it from other infections. This discovery has the potential to improve diagnostic tests and save lives in outbreak settings.
Researchers at Scripps Research create a nanodisc platform that preserves key parts of viral surface proteins, allowing for better understanding of antibody interactions. This approach can be applied to other viruses with similar membrane-embedded proteins, such as influenza and SARS-CoV-2.
Researchers at Kyoto University have detailed the structure of Borna disease virus 1's nucleoprotein-RNA complex, revealing a distinct binding mode and incremental model of viral replication. The study provides a molecular framework for targeting viral RNA synthesis and assembly.
Researchers at Penn State found that Ebola outbreaks are influenced by environmental and human factors, including weather patterns, vegetation health, and human movement. A strong positive correlation was found between the total length of roads and rivers in outbreak locations and the number of Ebola cases reported early in each outbreak.
Researchers discovered Marburg virus enters human cells up to 300 times more efficiently than Ebola, thanks to its unique entry protein. A nanobody has been identified to block its attachment to the receptor, providing a potential therapeutic strategy.
A new nanoparticle vaccine strategy has been developed to protect against multiple filovirus strains, including Ebola. The vaccine candidates display filovirus surface proteins on engineered nanoparticles, helping the immune system recognize and respond to the virus.
A new study found that both EBOV and MARV are capable of infecting human gut epithelial cells and disrupting fluid secretion, mirroring severe symptoms. The researchers developed a mini-gut model using induced pluripotent stem cells and discovered key signaling pathways involved in ion and fluid transport.
A WSU study found that over half of Sudan Ebola survivors suffer from debilitating health problems two years post-infection. The virus can persist in semen and breast milk for up to six months after recovery, raising concerns about transmission risks.
Scientists at CUNY ASRC develop novel synthetic carbohydrate receptors that block infection from seven different viruses across five unrelated families, including Ebola and SARS-CoV-2. The breakthrough offers a promising path toward the development of broad-spectrum antivirals.
Researchers at Kyoto University have captured the first high-resolution structure of Ebola's nucleocapsid using single-particle cryo-electron microscopy. This visualization reveals sophisticated interactions between structural components, including VP24 and NP proteins, which govern virus assembly, RNA synthesis, and transport.
Researchers at La Jolla Institute for Immunology have discovered a human antibody called mAb 3A6 that may prove useful against deadly outbreaks. The antibody was isolated from an Ebola survivor and found to block infection by binding to the viral stalk, offering protection at a very low dose.
A new retrospective study found that nearly half of patients with fever of unknown origin in sub-Saharan Africa had a detectable pathogen, including bacterial strains and hemorrhagic fever viruses. The study highlights the need for strengthened laboratory capacity to improve diagnosis and treatment.
A recent study published in Communications Biology reveals that the Sudan virus binds to human cells through a specific protein called NPC1, which enables it to attach with nine times greater affinity than Ebola. This discovery may contribute to the high fatality rate of the Sudan virus.
Researchers developed a new model to identify potential hosts of ebolaviruses, focusing on bat species with strong NPC1 protein binding and previous outbreak locations. The study uses large-scale binding assays and machine learning to guide future surveillance efforts.
Researchers at the University of Minnesota have developed two new nanobody inhibitors for Ebola: Nanosota-EB1 and Nanosota-EB2. These tiny antibodies target different parts of the virus, preventing it from attaching to cells and spreading. Lab tests show promising results, achieving a 100% survival rate in Ebola-infected mice.
Researchers at the University of Iowa Health Care have identified a cellular route used by Ebola virus to traverse skin layers and emerge onto the skin surface. The study suggests that the skin's surface may be one route of person-to-person transmission, with human skin specimens actively supporting EBOV infection.
Researchers at Rockefeller University have identified a novel class of antivirals that target a type of enzyme essential to SARS-CoV-2 infections and many RNA viruses, including Ebola and dengue. The findings may pave the way for a faster and more robust response to future pandemics.
Researchers at La Jolla Institute for Immunology have captured the first detailed images of the Ebola virus nucleocapsid structure, which is crucial for replicating in host cells. This breakthrough may accelerate the development of universal antivirals that target this viral structure to combat multiple filoviruses.
Effective public health communication is crucial for controlling the spread of disease, maintaining public trust, and encouraging compliance with health measures during epidemics. The African continent's diverse linguistic and cultural landscape requires tailored communication strategies to address social and economic factors.
Researchers found that Ebola virus creates tunneling nanotubes to transfer particles to new cells, evading treatments and spreading infection. The discovery suggests a new route of dissemination for the deadly virus.
Researchers at La Jolla Institute for Immunology have discovered the inner workings of Ebola virus replication inside host cells, revealing 'viral factories' that form clusters of viral proteins and genomes. These microscopic structures are formed in host cells and play a crucial role in the virus's life cycle.
Biologists argue that building on genomic sequencing momentum is critical in society's response to future pandemics. The technology improved during the COVID-19 pandemic, but gaps remain in global infrastructure and data sharing.
Heidelberg researchers have identified key proteins that can prevent the formation of fusion pores, allowing viruses like influenza A and Ebola to be trapped in a lipid membrane. This breakthrough could lead to new approaches for preventing infections with these highly infectious viruses.
A study published in Scientific Reports predicts that less than 20% of endangered mountain gorillas would survive more than 100 days past the first confirmed case of Ebola infection. Vaccination strategies are suggested to increase survival rates, with at least half of habituated gorillas vaccinated within three weeks of confirmation.
School of Veterinary Medicine researchers have identified a cellular pathway that hampers the Ebola virus' ability to exit human cells. By targeting the protein VP40, host cells activate autophagy, a process that digests and recycles proteins, reducing viral particle release into the bloodstream.
A new NIH-developed vaccine, VSV-SUDV, has been shown to completely protect cynomolgus macaques against a lethal Sudan virus challenge. The vaccine, based on the Ebola VSV vaccine concept, demonstrates cross-protective immune responses and provides rapid protective immunity to Sudan virus.
Researchers at La Jolla Institute for Immunology have discovered the detailed mechanism of action of Inmazeb, a three-antibody cocktail designed to combat Ebola virus infection. The study reveals new information about how the drug interacts with the virus and its potential effectiveness against additional species of Ebolavirus.
An experimental vaccine against Marburg virus demonstrated a good safety profile and induced strong, long-lasting immunity in a Phase 1 clinical trial. The vaccine candidate, cAd3-Marburg, induced an immune response in 95% of participants and maintained that response for over 48 weeks.
Aarthi Narayanan's team will use cutting-edge technology to identify potential therapeutics for illnesses triggered by hemorrhagic fever viruses, including Ebola. The project aims to develop artificial intelligence models and organ-on-chip platforms to test promising compounds.
Texas Biomed is at the forefront of developing a Sudan ebolavirus vaccine and antibody therapeutic to combat the ongoing outbreak in Uganda. The Institute has been awarded millions of dollars in contracts to run studies required for FDA approval, utilizing its BSL-4 laboratory facilities.
A large-scale randomized clinical trial confirms the safety of three Ebola vaccine regimens, inducing an immune response that persists for up to 12 months. The study suggests that vaccines can be a crucial tool in fighting the spread of the disease in sub-Saharan African countries.
The Ebola vaccine trials found all three regimens safe in both age groups, with antibody responses detectable for one year. The study enrolled over 3,100 volunteers in Guinea, Liberia, Sierra Leone, and Mali.
A new University of Colorado Boulder research warns that an obscure family of viruses in wild African primates may jump to humans, causing disease. The study focuses on simian arteriviruses, which have caused Ebola-like symptoms in monkeys and may attack immune cells like HIV.
A new study from the University of Maryland cautions that delayed interventions make it harder to eliminate monkeypox. The research suggests that stronger and better-adapted variants may evolve if case numbers are low, making it challenging to control outbreaks.
Researchers have created a stem cell-based model of the human liver, allowing for the study of how Ebola virus infects liver cells. The infected cultures showed that viral infection directly disrupts liver function, while immune cells can transfer the virus to other cells.
Using human stem cells, researchers investigated how the Ebola virus infects and damages the liver. The study found that major liver cell functions are compromised by Ebola virus infection and that the virus evades an early antiviral response, allowing it to replicate and cause damage.
A new study from Lehigh University found that social, economic, and demographic factors can predict an individual's propensity to engage in high-risk behaviors that expose them to Ebola spillover. The research identified young adults and those with agricultural jobs as the most at risk populations.
The Midwest Antiviral Drug Discovery Center, led by the University of Minnesota, aims to discover effective responses to pandemics through basic, translational, and clinical research. Researchers at UIC are developing an antiviral therapy for filoviruses like Ebola with a potential drug ready for human testing within three to five years.
Researchers found that retinal cells are more susceptible to Ebola virus infection than iris cells, which could lead to uveitis diagnosis and treatment. This discovery highlights the importance of monitoring retinal cells during acute viral infections to identify patients at high risk.
Researchers have developed a new tool that can quickly identify the presence of Ebola virus in blood samples, potentially leading to faster diagnosis and better outcomes. The technology uses optical microring resonators to detect tiny amounts of Ebola-related molecules at low levels.
Scientists have discovered a promising strategy to treat Ebola virus infections by targeting cellular protein GSPT1, which the virus hijacks for polymerase function. An experimental drug CC-90009 degrades GSPT1, halting viral multiplication.
Researchers at La Jolla Institute for Immunology have developed two human antibodies that target Ebola virus and Sudan virus, showing promise for a powerful antiviral therapy. The antibodies, 1C3 and 1C11, can block three glycoprotein sites on the virus at once and target the fusion machinery used by the viruses to infect host cells.
A groundbreaking study reveals that Ebola virus can hide in the brain ventricular system and cause fatal disease even after treatment. Persistent infection was found in about 20% of monkeys treated with antibody therapeutics, highlighting the need for long-term follow-up of survivors.
Researchers have developed a novel method for detecting viruses like Ebola and SARS CoV-2 using simple, inexpensive, and fast nano-sensors. The Nano2RED technology provides 10 times better sensitivity than existing ELISA tests and can be produced at a cost of around 1 cent per test.
A clinical trial found that convalescent plasma did not improve survival rates in most critically ill COVID-19 patients. However, immunocompromised patients showed a slight improvement with the treatment. The researchers speculate that too few high-quality antibodies and a runaway inflammatory immune response may be to blame.
Researchers have discovered a genetic mutation called retroCHMP3 that can block the replication of certain viruses like HIV and Ebola by disrupting their ability to exit an infected cell. This finding has the potential to lead to the development of new medical interventions against these deadly diseases.